SpectraDigital Reveals Patent for Chemical-Free Mastitis Detection

News provided by

Old Town Media

Jul 31, 2016, 03:00 ET

Fort Collins, Colo. (PRWEB) July 31, 2016 -- SpectraDigital Corporation, based in Guelph, Ontario, Canada and Fort Collins, Colorado announced the publication of a patent for a system to detect Mastitis without the use of chemical agents or other additive compounds.

The patent, entitled “Device and Process to Approximate Somatic Cell Count of Untreated Mammalian Milk,” uses rapid light-scattering technology to detect somatic counts in milk. SpectraDigital’s method may be integrated into in-line milking systems as well as used in the field on bench-top test kits, thanks to its easy integration into existing testing workflows.

“The application of a device which does not use additional chemicals such as dyes is a significant advancement in somatic cell detection,” Ed King, President, SpectraDigital, said.

The patent expands SpectraDigital’s portfolio into agricultural technology. The company, which is based jointly in Fort Collins and Guelph, Ontario, previously filed patents to detect malaria as well as a method to asses the efficacy of AIDS antivirals without relying on a PCR-based method.

This process expands SpectraDigital’s patent portfolio into the agricultural sector and underscores its expertise in light scattering-based methods. SpectraDigital holds patents related to a malaria diagnostic as well as a method to assess the efficacy of AIDS antivirals without relying on a PCR-based method.

SpectraDigital is now pursuing partnerships aimed at commercialization of this technology.

About SpectraDigital

SpectraDigital Corporation (SDC) is a technology company that specializes in the development of simple, easy-to-use, medical diagnostic tests for use in low-resource settings. SDC is also actively engaged in developing agricultural applications.

The SpectraDigital platform can be adapted for use in a variety of applications. HIV SpectraPoint, is our first application that assesses the efficacy of AIDS anti-virals using a simple blood test. This method can provide information similar to the genotype/phenotype test at a much lower cost making access to diagnostics more accessible.

Other uses for SDC’s platform include developing lead chemistries, drug assessment, evaluating the efficacy of drugs, environmental monitoring, and other settings involving the measurement of cellular reactions and cellular response to metabolic agents.

Advantages of SDC’s technology platform include:

  • Adaptive to a variety of settings ranging from blood to pathogens
  • Speed of analysis. Research time can be significantly reduced as light scattering measurements are inherently rapid and offer superior speed of analysis.
  • Portability. Rugged equipment can be transported to any research lab or field site. An internet connection can facilitate remote assistance with SDC headquarters for quality control and analysis.
  • Reduced Cost. Design with low-cost components provides a robust technology platform for a very low cost.

Kerrie Luginbill, Old Town Media, +1 970-568-5250, [email protected]